

# Biotron Limited

ACN 086 399 144

## SUPPLEMENTARY PROSPECTUS

### Important Information

This is a supplementary prospectus (**Supplementary Prospectus**) intended to be read with the prospectus dated 3 March 2025 (**Prospectus**) issued by Biotron Limited (**Company**).

This Supplementary Prospectus is dated 5 March 2025 and was lodged with the Australian Securities and Investments Commission (**ASIC**) on that day. Neither ASIC nor ASX (and their respective officers) take any responsibility as to the contents of this Supplementary Prospectus.

To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus.

This is an important document and should be read in its entirety. If you do not understand it you should consult your professional advisors without delay.

---

### 1 REVISED TIMETABLE

On 5 March 2025 the Company extended the Offer Closing Date to 5pm AEDT 25 March 2025. As a result, the following timetable applies to the Offer:

Record date to determine Entitlement (Record Date)	7pm AEDT 6 March 2025
Prospectus with Entitlement and Acceptance Form sent to Eligible Shareholders	10 March 2025
Offer opens for receipt of Applications	10 March 2025
Rights trading ends at close of trading	18 March 2025
Unless otherwise determined by ASX, new shares quoted on a deferred settlement basis from market open.	19 March 2025
Latest date to extend the Rights Issue	20 March 2025
Closing date for acceptances	5pm AEDT 25 March 2025

Announce results of the Rights Issue	1 April 2025
Issue of New Shares	1 April 2025
Normal trading of New Shares expected to commence	2 April 2025
Dispatch of shareholding statements	2 April 2025
Last date to issue Shortfall Shares (see section 8.6 of the Prospectus)	25 June 2025

**Note:** The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date, subject to such date being no later than 3 months after the date of the Prospectus. As such the date the New Shares are expected to commence trading on ASX may vary.

The Directors do not consider the circumstances disclosed in this Supplementary Prospectus to be materially adverse from the point of view of an investor, and no withdrawal rights will be offered to investors.

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors. In accordance with section 720 of the Corporations Act, each Director has consented to the lodgment of this Supplementary Prospectus with ASIC.

Dated: 5 March 2025



.....

Signed for and on behalf of Biotron Limited  
By Dr Michelle Miller  
Managing Director